Everything below concerns evidence gap. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-03. Numbers and descriptions here follow the published literature rather than marketing material.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
| Property | Value | Notes |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Sequence corresponds to a fifteen-residue portion of the parent protein |
| Sequence | GEPPPGKPADDAGLV | Single linear chain, fifteen amino acids |
| Reported molecular weight | About 1419 daltons | Value quoted consistently in supplier and review literature |
| Regulatory status | Not an approved human medicine in the US or EU | Handled and sold as a research chemical |
| Sports status | Listed as prohibited | Falls under non-approved-substance categories in anti-doping codes |
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
The heavily phosphorylated β-sheet of caddisfly larvae contains strong negative charges which have been found to interact with di- and trivalent cations found naturally within the larvae's aquatic environment. These cations, including calcium, magnesium, and iron, are vital to maintaining the rigid structure of the silk's β-sheet. The ionic interactions between negatively charged serines and these cations produce a crystal with a unit cell of 5.9 Angstroms x 23.3 Angstroms x 17.3 Angstroms, as determined by X-Ray diffraction. The necessity of these cations was shown using EDTA to chelate and remove them from the protein structure, producing a mobile, noncrystalline protein. Reintroduction of monovalent ions failed to restore the crystalline structure, however reintroduction of calcium or other multivalent ions successfully restored the rigidity to the H-fibroin protein.
Despite being intended as a short bonus feature of the compilation, it was considered the highlight of the collection. Its success led to the creation of the much longer and more in-depth Portal 2, which included both single player and cooperative multiplayer modes. In addition to the challenging puzzle elements, both games are praised for their dark humor, written by Erik Wolpaw, Chet Faliszek, and Jay Pinkerton, with notable voice work by actors Ellen McLain, Stephen Merchant, and J. K. Simmons. A number of spin-off media productions have been developed alongside the games, and several of the game's iconic elements have become parts of internet memes.
Certain progestins, namely cyproterone acetate and medroxyprogesterone acetate and as described previously, are used at high doses as functional antiandrogens due to their antigonadotropic effects to help suppress testosterone levels in transgender women. Aside from the specific use of testosterone suppression however, there are no other indications of progestogens in transgender women at present. In relation to this, the use of progestogens in transgender women is controversial, and they are not otherwise routinely prescribed or recommended. Besides progesterone, cyproterone acetate, and medroxyprogesterone acetate, other progestogens that have been reported to have been used in transgender women include hydroxyprogesterone caproate, dydrogesterone, norethisterone acetate, and drospirenone. Progestins in general largely have the same progestogenic effects however, and in theory, any progestin could be used in transgender women. Clinical research on the use of progestogens in transgender women is very limited. Some patients and clinicians believe, on the basis of anecdotal and subjective claims, that progestogens may provide benefits such as improved breast and/or nipple development, mood, and libido in transgender women. There are no clinical studies to support such reports at present. No clinical study has assessed the use of progesterone in transgender women, and only a couple of studies have compared the use of progestins (specifically cyproterone acetate and medroxyprogesterone acetate) versus the use of no progestogen in transgender women.
Sources: en.wikipedia.org
The spleen initially becomes noticeably swollen, but the lack of a healthy blood flow through the organ culminates in scarring of the spleen tissues and eventually death of the organ, generally before the age of 5 years. The actual anaemia of the illness is caused by haemolysis, the destruction of the red cells, because of their shape. Although the bone marrow attempts to compensate by releasing new red cells, the rate of destruction exceeds this. Healthy red blood cells typically function for 90–120 days; however, sickled cells only last 10–20 days. The rapid breakdown of RBCs in sickle cell disease results in the release of free heme into the bloodstream, exceeding the body's protective mechanisms. Although heme is an essential component of haemoglobin, it is also a potent oxidative molecule. Free heme is also an alarmin – a signal of tissue damage or infection, which triggers defensive responses in the body and increases the risk of inflammation and vaso-occlusive events.
Wittner (1962), historian on peace movements Peter Winn (1962), professor of history at Tufts University Richard Alba (1963), sociologist, professor at Graduate Center, CUNY David Berlinski (1963), mathematician, professor Eric Foner (1963), preeminent historian of Reconstruction, winner of the Pulitzer Prize for History and former president of American Historical Association David Orme-Johnson (1963), professor of psychology at the Maharishi University of Management Michael Klare (1963), professor of security studies at Hampshire College Victor Margolin (1963), professor of design history at the University of Illinois at Chicago Jonah Raskin (1963), writer, professor on counterculture Howard Spodek (1963), historian specializing in urban studies; professor at Temple University Robert J. Art (1964), professor of international relations at Brandeis University Richard P. Appelbaum (1964), professor of sociology at University of California, Santa Barbara Jonathan R. Cole (1964), sociologist and provost of Columbia University 1989–2003 Peter S. Donaldson (1964), professor of English literature at the Massachusetts Institute of Technology Richard Epstein (1964), libertarian law scholar Richard S. Kayne (1964), professor of linguistics at New York University Peter Kolchin (1964), professor at the University of Delaware and winner of the 1988 Bancroft Prize John H. Langbein (1964), Sterling Professor at Yale Law School Peter K.
== Techniques for data analysis == Global proteome profiling is the direct representation of the protein set in an organism, organ, tissues, or an organelle. Among the primary goals of proteomic analysis is to compare and determine the relative quantities of proteins under a defined set of conditions. Over the last 4 decades, two-dimensional gel electrophoresis has gained popularity because it successfully helped differential proteomics provide visual proof of changes in protein abundance that cannot be predicted from genome analysis. Each protein spot on a 2-DE gel can be analyzed based on its abundance, location, or even presence and absence. This flexible gel-based method combines and makes use of the best principle for separation of protein complexes based on their charge and mass, visual mapping coupled with successful mass spectrometric identification of individual proteins. Latest developments in proteomics have paved the way for the discovery of techniques such as colocalization analysis (COLA), which detects protein–protein co-localizations at a global scale. This helps map interactome dynamics under various conditions, making it possible to understand protein interactions and functions. Proteomic profiling relates to each individual's physiological changes by the monitoring of protein expression variations according to factors such as aging, exercise, and environmental conditions. For example, in aging muscle, proteomic analysis showed changes in protein isoforms and altered metabolic pathways that indicate adaptations in muscle functions and energy metabolism.
Sources: en.wikipedia.org
== Operation == To use a slow cooker, the cook places raw food and a liquid, such as stock, water, or wine, in the slow cooker. Some recipes call for pre-heated liquid. The cook puts the lid on the slow cooker and turns it on. Some cookers automatically switch from cooking to warming (maintaining the temperature at 71–74 °C (160–165 °F)) after a fixed time or after the internal temperature of the food, as determined by a probe, reaches a specified value. The heating element heats the contents to a steady temperature in the 79–93 °C (174–199 °F) range. The contents are enclosed by the crock and the lid, and attain an essentially constant temperature. The vapor that is produced at this temperature condenses on the bottom of the lid and returns as liquid, into which some water-soluble vitamins are leached. The liquid transfers heat from the pot walls to its contents, and also distributes flavors. The slow cooker's lid is essential to prevent the warm vapor from escaping, taking heat with it and cooling the contents. Basic cookers, which have only high, medium, low, or keep warm settings and must be turned on and off manually. More advanced cookers have computerized timing devices that let a cook program the cooker to perform multiple operations, such as two hours high, followed by two hours low, followed by warm, and to delay the start of cooking. Because food cooked in a slow cooker stays warm for a long time after it is switched off, people can use the slow cookers to take food elsewhere to eat without reheating.
=== Neuromuscular adaptations === Strength training is not only associated with an increase in muscle mass, but also an improvement in the nervous system's ability to recruit muscle fibers and activate them at a faster rate. Neural adaptations can occur in the motor cortex, the spinal cord, and/or neuromuscular junctions. The initial significant improvements in strength amongst new lifters are a result of increased neural drive, motor unit synchronization, motor unit excitability, rate of force development, muscle fiber conduction velocity, and motor unit discharge rate. Together, these improvements provide an increase in strength separate from muscle hypertrophy. Typically, the main barbell lifts – squat, bench, and deadlift – are performed with a full range of motion, which provides the greatest neuromuscular improvements compared to one-third or two-thirds range of motion. However, there are reasons to perform these lifts with less range of motion, particularly in the powerlifting community. By limiting range of motion, lifters can target a specific joint angle in order to improve their sticking points by training their neural drive. Neuromuscular adaptations are critical for the development of strength, but are especially important in the aging adult population, as the decline in neuromuscular function is roughly three times as great (≈3% per year) as the loss of muscle mass (≈1% per year). By staying active and following a resistance training program, older adults can maintain their movement, stability, balance, and independence.
== Research and partnerships == Mondobiotech investigated whether information already published about naturally occurring human substances could suggest new uses in rare diseases. A 2010 case study by researchers at the University of St. Gallen described its use of scientific literature, external researchers and laboratories, and licensing partners instead of maintaining a conventional in-house laboratory operation. Financial news reporting also described the company's approach as searching medical databases for drug candidates and licensing rights to other companies. In 2002, Mondobiotech and InterMune agreed to collaborate on interferon gamma-1b research for pulmonary diseases, including asthma; the arrangement also covered specified patent rights relating to idiopathic pulmonary fibrosis. In 2006, Biogen Idec licensed rights to develop aviptadil for pulmonary arterial hypertension. The agreement included a US$7.5 million upfront payment and up to US$30 million in possible development and commercialization milestones; the milestone amount was conditional, not a payment already received. Biogen stated in a later regulatory filing that it ended its participation in the aviptadil development program in December 2009. In February 2010, Mondobiotech entered a partnership with Lung Rx, a subsidiary of United Therapeutics, for further development of aviptadil. The company also agreed in 2009 to have Bachem develop and manufacture peptides for its research programs.
Sources: en.wikipedia.org
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.
The peptide was named after a protein fraction found in human gastric juice, and the shorter form was called body protection compound. That phrase was shortened to the abbreviation BPC. The number 157 refers to a laboratory designation used in the original isolation work.
Its sequence corresponds to a segment of a protein present in gastric secretions, but the material supplied for research is made synthetically. No commercial product is purified from human or animal tissue. The synthetic route is used because it gives a defined chain length and a reproducible sequence.
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.